Felicia Cosman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Felicia Cosman has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
- Jeri W. Nieves
Hospital for Special Surgery (HSS), New York, USA
10 shared publications - David W. Dempster
Regional Bone Center Helen Hayes Hospital West Haverstraw NY USA
6 shared publications - Bruce Mitlak
Radius Health, Inc. Boston MA USA
4 shared publications - Bente Lomholt Langdahl
Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark
3 shared publications - Cesar Libanati
UCB Pharma, Brussels, Belgium
3 shared publications David W. Dempster
Regional Bone Center, Helen Hayes Hospital, 55 N Route 9W, West Haverstraw, NY 10993, USA
3 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Springer Nature in Osteoporosis International
- p. 1-14
Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial
- 20 August 2026
- Published by Springer Nature in Osteoporosis International
- p. 1-14
Open AccessAbaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial
- 25 April 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Intratrabecular bone remodeling—a previously overlooked mode of remodeling hyperactivated by parathyroid hormone
Currently, no consensus exists on either terminology, definition, or the biological significance of the phenomena intratrabecular tunneling. Despite this, observations of intratrabecular tunneling are frequently reported in literature covering diseases or treatments involving parathyroid hormone (PTH) or kidneys. A few attempts to quantify this phenomena have been made mainly based on bone resorption, despite the concurrent presence of bone formation. This study demonstrates that intratrabecular tunneling is a previously unrecognized physiological mode of intratrabecular bone remodeling occurring across conditions and ages. Similar to intracortical remodeling, it is induced by PTH-treatment and creates an extensive interconnected tunnel-network that hollows out the trabeculae. This study primarily utilizes iliac crest bone biopsies collected from a clinical trial, where patients with hypoparathyroidism were randomized to receive daily injections with either 100 μg rhPTH(1-84) or placebo as add-on to conventional therapy for 6 mo. In addition, further bone biopsies were collected from a 24-mo open-label extension study, including patients receiving either only conventional treatment, continued rhPTH-treatment or discontinued rhPTH-treatment. Histomorphometry demonstrated that PTH-treatment induced an 18-fold and 36-fold increase in intratrabecular porosity after 6 and 30 mo of treatment, respectively. After 6-mo of PTH- vs conventional treatment, a median 7.7% vs 0.0% were eroded pores, 69.1% vs 0.0% were eroded-formative pores, 12.9% vs 0.0% were formative pores, and 0.9% vs 81.2% were quiescent pores. PTH-treatment withdrawal normalized the intratrabecular remodeling to levels similar to conventional therapy. The intratrabecular remodeling mainly occurred in plates and junctions of trabeculae, and not in trabecular rods. Intratrabecular remodeling parameters showed a positive correlation with PTH-induced trabecular mineralization and a negative correlation with active vitamin D-supplementary doses. Dynamics of the PTH-induced intratrabecular remodeling could be tracked using time-lapsed synchrotron radiation μCT in a rabbit model and the complexity of the trabecular strain environment was confirmed with micro-finite element analysis.
- 25 April 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Intratrabecular bone remodeling—a previously overlooked mode of remodeling hyperactivated by parathyroid hormone
Currently, no consensus exists on either terminology, definition, or the biological significance of the phenomena intratrabecular tunneling. Despite this, observations of intratrabecular tunneling are frequently reported in literature covering diseases or treatments involving parathyroid hormone (PTH) or kidneys. A few attempts to quantify this phenomena have been made mainly based on bone resorption, despite the concurrent presence of bone formation. This study demonstrates that intratrabecular tunneling is a previously unrecognized physiological mode of intratrabecular bone remodeling occurring across conditions and ages. Similar to intracortical remodeling, it is induced by PTH-treatment and creates an extensive interconnected tunnel-network that hollows out the trabeculae. This study primarily utilizes iliac crest bone biopsies collected from a clinical trial, where patients with hypoparathyroidism were randomized to receive daily injections with either 100 μg rhPTH(1-84) or placebo as add-on to conventional therapy for 6 mo. In addition, further bone biopsies were collected from a 24-mo open-label extension study, including patients receiving either only conventional treatment, continued rhPTH-treatment or discontinued rhPTH-treatment. Histomorphometry demonstrated that PTH-treatment induced an 18-fold and 36-fold increase in intratrabecular porosity after 6 and 30 mo of treatment, respectively. After 6-mo of PTH- vs conventional treatment, a median 7.7% vs 0.0% were eroded pores, 69.1% vs 0.0% were eroded-formative pores, 12.9% vs 0.0% were formative pores, and 0.9% vs 81.2% were quiescent pores. PTH-treatment withdrawal normalized the intratrabecular remodeling to levels similar to conventional therapy. The intratrabecular remodeling mainly occurred in plates and junctions of trabeculae, and not in trabecular rods. Intratrabecular remodeling parameters showed a positive correlation with PTH-induced trabecular mineralization and a negative correlation with active vitamin D-supplementary doses. Dynamics of the PTH-induced intratrabecular remodeling could be tracked using time-lapsed synchrotron radiation μCT in a rabbit model and the complexity of the trabecular strain environment was confirmed with micro-finite element analysis.
- Open Access
- 11 April 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (6)
Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis
This randomized, double-blind, multicenter Phase 3 trial evaluated the efficacy, safety, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of Bmab 1000 vs reference denosumab in 479 women with postmenopausal osteoporosis. Participants (mean age 66.6 yr; lumbar spine T-score ≤−2.5 to ≥−4.0) were randomized 1:1 to receive 60 mg Bmab 1000 (n = 238) or reference denosumab (n = 241) subcutaneously. The study comprised 2 parts: Part 1 (weeks 0-52) evaluated therapeutic and PD equivalence between Bmab 1000 and reference denosumab using percentage change from baseline (%CfB) in lumbar spine bone mineral density (BMD) at week 52 and area under the effect curve (AUEC) of serum C-terminal telopeptide of Type 1 collagen (sCTX) from baseline to 26 wk following dosing on day 1 and week 26. Part 2 (weeks 52-78) re-randomized those on reference denosumab to either continue or switch to Bmab 1000 (n = 104 each), while those on Bmab 1000 continued treatment (n = 218). Part 2 monitored the safety of Bmab 1000 and reference denosumab after transition from reference denosumab to Bmab 1000 vs continuing reference denosumab. Secondary analyses included additional efficacy, PD, PK, safety, and immunogenicity parameters. At week 52, the confidence intervals (CIs) for the difference in least square means (LSMs) in %CfB in lumbar spine BMD between Bmab 1000 and reference denosumab were contained within the predefined margins (±1.45; LSM diff: 0.610, 95% CI: −0.095, 1.316), indicating therapeutic equivalence. The sCTX AUEC up to 26 wk for Bmab 1000 and reference denosumab were similar (geometric LSM ratio: 104.14; 95% CI: 97.76, 110.95). The secondary results were comparable among all groups up to week 78, including after transitioning to Bmab 1000 from reference denosumab. In conclusion, Bmab 1000 demonstrated equivalent efficacy and PD to reference denosumab, with similar PK, safety, and immunogenicity profiles. There was no effect of transitioning from reference denosumab to Bmab 1000. Clinical trial registration: EudraCT number: 2021-006545-36, CT.gov number: NCT05345691.
- 11 April 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (6)
Open AccessEfficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis
This randomized, double-blind, multicenter Phase 3 trial evaluated the efficacy, safety, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of Bmab 1000 vs reference denosumab in 479 women with postmenopausal osteoporosis. Participants (mean age 66.6 yr; lumbar spine T-score ≤−2.5 to ≥−4.0) were randomized 1:1 to receive 60 mg Bmab 1000 (n = 238) or reference denosumab (n = 241) subcutaneously. The study comprised 2 parts: Part 1 (weeks 0-52) evaluated therapeutic and PD equivalence between Bmab 1000 and reference denosumab using percentage change from baseline (%CfB) in lumbar spine bone mineral density (BMD) at week 52 and area under the effect curve (AUEC) of serum C-terminal telopeptide of Type 1 collagen (sCTX) from baseline to 26 wk following dosing on day 1 and week 26. Part 2 (weeks 52-78) re-randomized those on reference denosumab to either continue or switch to Bmab 1000 (n = 104 each), while those on Bmab 1000 continued treatment (n = 218). Part 2 monitored the safety of Bmab 1000 and reference denosumab after transition from reference denosumab to Bmab 1000 vs continuing reference denosumab. Secondary analyses included additional efficacy, PD, PK, safety, and immunogenicity parameters. At week 52, the confidence intervals (CIs) for the difference in least square means (LSMs) in %CfB in lumbar spine BMD between Bmab 1000 and reference denosumab were contained within the predefined margins (±1.45; LSM diff: 0.610, 95% CI: −0.095, 1.316), indicating therapeutic equivalence. The sCTX AUEC up to 26 wk for Bmab 1000 and reference denosumab were similar (geometric LSM ratio: 104.14; 95% CI: 97.76, 110.95). The secondary results were comparable among all groups up to week 78, including after transitioning to Bmab 1000 from reference denosumab. In conclusion, Bmab 1000 demonstrated equivalent efficacy and PD to reference denosumab, with similar PK, safety, and immunogenicity profiles. There was no effect of transitioning from reference denosumab to Bmab 1000. Clinical trial registration: EudraCT number: 2021-006545-36, CT.gov number: NCT05345691.
- Top Cited PapersOpen Access
- 27 January 2026
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 77 (1) , 433-448
Recent Advances in Osteoporosis Therapeutics
Postmenopausal osteoporosis is a chronic progressive disease related to estrogen deficiency at menopause, aging, and superimposed genetic and environmental factors. Many patients with osteoporosis are not diagnosed, and the majority are not treated. Current therapies for osteoporosis include antiresorptive treatments, including bisphosphonates, denosumab, and raloxifene, and osteoanabolic treatments, including teriparatide, abaloparatide, and romosozumab, which is a dual-action agent. Sequential therapies aim to optimize fracture prevention and bone density outcomes for long-term management. Recent guidelines have suggested categorical risk stratification and a goal-directed individualized therapy strategy. New treatments under investigation also hold promise for further improving bone health in postmenopausal osteoporosis.
- 27 January 2026
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 77 (1) , 433-448
Top Cited PapersOpen AccessRecent Advances in Osteoporosis Therapeutics
Postmenopausal osteoporosis is a chronic progressive disease related to estrogen deficiency at menopause, aging, and superimposed genetic and environmental factors. Many patients with osteoporosis are not diagnosed, and the majority are not treated. Current therapies for osteoporosis include antiresorptive treatments, including bisphosphonates, denosumab, and raloxifene, and osteoanabolic treatments, including teriparatide, abaloparatide, and romosozumab, which is a dual-action agent. Sequential therapies aim to optimize fracture prevention and bone density outcomes for long-term management. Recent guidelines have suggested categorical risk stratification and a goal-directed individualized therapy strategy. New treatments under investigation also hold promise for further improving bone health in postmenopausal osteoporosis.
- 20 September 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (11) , 2331-2336
Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trial
Summary The osteoanabolic effects of teriparatide are maximal in the first 6 months of treatment. This secondary analysis of a randomized clinical trial investigated whether cyclic teriparatide would improve Trabecular Bone Score (TBS) more than standard dosing over 36 months. Results showed similar improvements in TBS with both teriparatide regimens. Introduction The effects of teriparatide (TPTD) are maximal in the first 6 months when bone formation exceeds resorption to the greatest degree. Cyclic use of TPTD was proposed to try to broaden this anabolic window. Prior results from this study showed that 6-month cycles of TPTD and denosumab did not improve BMD compared to standard dosing with TPTD followed by denosumab. The goal of this study was to determine if there was any difference in trabecular bone score improvement (TBS) with cyclic vs standard therapy. Methods 70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32). DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit. This paper is a post-hoc analysis of a prior clinical trial looking at BMD change at 36 months for cyclic vs. standard dosing. Results At baseline, TBS was similar between the 2 groups with mean level 1.24 ± 0.05, considered partially degraded. In the standard group, TBS increased by 1.1% at 18 months (p = 0.11 vs baseline) and 1.6% at 36 months (p < 0.11 vs baseline). In the cyclic group, TBS increased by 2.4% and 2.6% at 18 and 36 months from baseline, respectively (both p < 0.05 vs. baseline). However, there were no group differences in TBS increments at either 18 or 36 months. At 36 months, 17 total participants had improvement in their TBS category from either degraded to partially degraded or partially degraded to normal, or degraded to normal with 4 deteriorations to a lower category. There was no difference between groups in the TBS category change. Conclusion TBS improved similarly with cyclic and standard treatment regimens of TPTD and denosumab over 36 months, however possible differences may have been masked by inadequate study power.
- 20 September 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (11) , 2331-2336
Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trial
Summary The osteoanabolic effects of teriparatide are maximal in the first 6 months of treatment. This secondary analysis of a randomized clinical trial investigated whether cyclic teriparatide would improve Trabecular Bone Score (TBS) more than standard dosing over 36 months. Results showed similar improvements in TBS with both teriparatide regimens. Introduction The effects of teriparatide (TPTD) are maximal in the first 6 months when bone formation exceeds resorption to the greatest degree. Cyclic use of TPTD was proposed to try to broaden this anabolic window. Prior results from this study showed that 6-month cycles of TPTD and denosumab did not improve BMD compared to standard dosing with TPTD followed by denosumab. The goal of this study was to determine if there was any difference in trabecular bone score improvement (TBS) with cyclic vs standard therapy. Methods 70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32). DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit. This paper is a post-hoc analysis of a prior clinical trial looking at BMD change at 36 months for cyclic vs. standard dosing. Results At baseline, TBS was similar between the 2 groups with mean level 1.24 ± 0.05, considered partially degraded. In the standard group, TBS increased by 1.1% at 18 months (p = 0.11 vs baseline) and 1.6% at 36 months (p < 0.11 vs baseline). In the cyclic group, TBS increased by 2.4% and 2.6% at 18 and 36 months from baseline, respectively (both p < 0.05 vs. baseline). However, there were no group differences in TBS increments at either 18 or 36 months. At 36 months, 17 total participants had improvement in their TBS category from either degraded to partially degraded or partially degraded to normal, or degraded to normal with 4 deteriorations to a lower category. There was no difference between groups in the TBS category change. Conclusion TBS improved similarly with cyclic and standard treatment regimens of TPTD and denosumab over 36 months, however possible differences may have been masked by inadequate study power.
- Open Access
- 11 April 2025
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 40 (6) , 773-778
Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide
The goal of treatment for women at high risk of fracture who have a T-score ≤−2.5 is to mitigate fracture risk by achieving T-scores at least above −2.5. In the ACTIVE trial, 2463 women with osteoporosis aged 49-86 yr were treated for 18 mo with abaloparatide (80 μg), teriparatide (20 μg), or placebo. In ACTIVExtend, eligible women from the abaloparatide and placebo groups received weekly treatment with 70 mg of alendronate for 2 additional years. This post hoc analysis of ACTIVE and ACTIVExtend included women with baseline TH or LS T-scores ≤−2.5. Logistic regression was used to predict the probability of achieving a T-score >−2.5 at the TH or LS during 18 mo of treatment with abaloparatide or teriparatide and during 3.5 yr with the sequence of abaloparatide/alendronate compared to placebo/alendronate. At baseline, 23% and 74% of women enrolled in ACTIVE had T-scores ≤−2.5 at the TH and LS, respectively. Over 18 mo of treatment, more than 50% of women were likely to achieve TH T-scores >−2.5, with baseline TH T-scores as low as −2.7 for both abaloparatide and teriparatide. More than 50% of women were predicted to achieve an LS T-score >−2.5 with a baseline LS T-score as low as −3.3 for abaloparatide or −3.2 on teriparatide. Over 3.5 yr of sequential treatment with abaloparatide/alendronate, >50% of women with baseline TH T-scores ≥−2.9 and LS T-scores ≥−3.5 were predicted to achieve T-scores >−2.5, respectively. A patient’s BMD at baseline and the probability of achieving target T-scores with treatment should be considered when determining that treatment should be initiated in patients at high or very high risk of fracture.
- 11 April 2025
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 40 (6) , 773-778
Open AccessProbability of achieving bone mineral density treatment targets with abaloparatide and teriparatide
The goal of treatment for women at high risk of fracture who have a T-score ≤−2.5 is to mitigate fracture risk by achieving T-scores at least above −2.5. In the ACTIVE trial, 2463 women with osteoporosis aged 49-86 yr were treated for 18 mo with abaloparatide (80 μg), teriparatide (20 μg), or placebo. In ACTIVExtend, eligible women from the abaloparatide and placebo groups received weekly treatment with 70 mg of alendronate for 2 additional years. This post hoc analysis of ACTIVE and ACTIVExtend included women with baseline TH or LS T-scores ≤−2.5. Logistic regression was used to predict the probability of achieving a T-score >−2.5 at the TH or LS during 18 mo of treatment with abaloparatide or teriparatide and during 3.5 yr with the sequence of abaloparatide/alendronate compared to placebo/alendronate. At baseline, 23% and 74% of women enrolled in ACTIVE had T-scores ≤−2.5 at the TH and LS, respectively. Over 18 mo of treatment, more than 50% of women were likely to achieve TH T-scores >−2.5, with baseline TH T-scores as low as −2.7 for both abaloparatide and teriparatide. More than 50% of women were predicted to achieve an LS T-score >−2.5 with a baseline LS T-score as low as −3.3 for abaloparatide or −3.2 on teriparatide. Over 3.5 yr of sequential treatment with abaloparatide/alendronate, >50% of women with baseline TH T-scores ≥−2.9 and LS T-scores ≥−3.5 were predicted to achieve T-scores >−2.5, respectively. A patient’s BMD at baseline and the probability of achieving target T-scores with treatment should be considered when determining that treatment should be initiated in patients at high or very high risk of fracture.
- Open Access
- 25 January 2025
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 40 (6) , 766-772
Probability of achieving bone mineral density treatment goals with denosumab treatment in postmenopausal women with osteoporosis
BMD levels achieved on osteoporosis treatment are predictive of subsequent fracture risk, and T-score >−2.5 has been proposed as a minimum treatment target for women with osteoporosis. Knowing the likelihood of attaining target T-scores with different medications for different baseline BMD levels can help determine appropriate initial treatment for individual patients. In this post hoc analysis, we estimated the probability of achieving a non-osteoporotic T-score (>−2.5 or ≥−2.0) at the TH or LS in postmenopausal women >60 yr old treated with denosumab for either 3 or 10 yr in the FREEDOM trial and its long-term extension. In women with baseline TH T-scores of −2.7, −3.0, and −3.5, the probabilities of achieving target T-scores >−2.5 with 3 yr of denosumab were 71%, 12%, and 0.1%, respectively. At LS, for baseline T-scores of −2.7, −3.0, and −3.5, the probabilities were 86%, 59%, and 11%, respectively. Longer treatment duration of up to 10 yr increased the probability of achieving target T-scores. The baseline T-scores that permitted at least 50% of women to achieve a target T-score >−2.5 were −2.8 at TH and −3.1 at LS after 3 yr and −3.0 at TH and −3.7 at LS after 10 yr of treatment. To achieve higher treatment targets (T-scores ≥ −2.0), overall probabilities were lower at both skeletal sites, particularly for TH, even with longer treatment duration. Our results demonstrate that the probability of achieving T-score targets with denosumab is dependent on baseline BMD, skeletal site, and treatment duration. Knowing the probability of achieving treatment targets for different baseline TH and LS T-scores can help determine whether denosumab is an appropriate first choice of treatment in individual patients.
- 25 January 2025
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 40 (6) , 766-772
Open AccessProbability of achieving bone mineral density treatment goals with denosumab treatment in postmenopausal women with osteoporosis
BMD levels achieved on osteoporosis treatment are predictive of subsequent fracture risk, and T-score >−2.5 has been proposed as a minimum treatment target for women with osteoporosis. Knowing the likelihood of attaining target T-scores with different medications for different baseline BMD levels can help determine appropriate initial treatment for individual patients. In this post hoc analysis, we estimated the probability of achieving a non-osteoporotic T-score (>−2.5 or ≥−2.0) at the TH or LS in postmenopausal women >60 yr old treated with denosumab for either 3 or 10 yr in the FREEDOM trial and its long-term extension. In women with baseline TH T-scores of −2.7, −3.0, and −3.5, the probabilities of achieving target T-scores >−2.5 with 3 yr of denosumab were 71%, 12%, and 0.1%, respectively. At LS, for baseline T-scores of −2.7, −3.0, and −3.5, the probabilities were 86%, 59%, and 11%, respectively. Longer treatment duration of up to 10 yr increased the probability of achieving target T-scores. The baseline T-scores that permitted at least 50% of women to achieve a target T-score >−2.5 were −2.8 at TH and −3.1 at LS after 3 yr and −3.0 at TH and −3.7 at LS after 10 yr of treatment. To achieve higher treatment targets (T-scores ≥ −2.0), overall probabilities were lower at both skeletal sites, particularly for TH, even with longer treatment duration. Our results demonstrate that the probability of achieving T-score targets with denosumab is dependent on baseline BMD, skeletal site, and treatment duration. Knowing the probability of achieving treatment targets for different baseline TH and LS T-scores can help determine whether denosumab is an appropriate first choice of treatment in individual patients.
- Top Cited PapersOpen Access
- 29 July 2024
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (10) , 1393-1405
Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024
The overarching goal of osteoporosis management is to prevent fractures. A goal-directed approach to long-term management of fracture risk helps ensure that the most appropriate initial treatment and treatment sequence is selected for individual patients. Goal-directed treatment decisions require assessment of clinical fracture history, vertebral fracture identification (using vertebral imaging as appropriate), measurement of bone mineral density (BMD), and consideration of other major clinical risk factors. Treatment targets should be tailored to each patient’s individual risk profile and based on the specific indication for beginning treatment, including recency, site, number and severity of prior fractures, and BMD levels at the total hip, femoral neck, and lumbar spine. Instead of first-line bisphosphonate treatment for all patients, selection of initial treatment should focus on reducing fracture risk rapidly for patients at very high and imminent risk, such as in those with recent fractures. Initial treatment selection should also consider the probability that a BMD treatment target can be attained within a reasonable period of time and the differential magnitude of fracture risk reduction and BMD impact with osteoanabolic versus antiresorptive therapy. This position statement of the ASBMR/BHOF Task Force on Goal-Directed Osteoporosis Treatment provides an overall summary of the major clinical recommendations about treatment targets and strategies to achieve those targets based on the best evidence available, derived primarily from studies in older postmenopausal women of European ancestry.
- 29 July 2024
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (10) , 1393-1405
Top Cited PapersOpen AccessGoal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024
The overarching goal of osteoporosis management is to prevent fractures. A goal-directed approach to long-term management of fracture risk helps ensure that the most appropriate initial treatment and treatment sequence is selected for individual patients. Goal-directed treatment decisions require assessment of clinical fracture history, vertebral fracture identification (using vertebral imaging as appropriate), measurement of bone mineral density (BMD), and consideration of other major clinical risk factors. Treatment targets should be tailored to each patient’s individual risk profile and based on the specific indication for beginning treatment, including recency, site, number and severity of prior fractures, and BMD levels at the total hip, femoral neck, and lumbar spine. Instead of first-line bisphosphonate treatment for all patients, selection of initial treatment should focus on reducing fracture risk rapidly for patients at very high and imminent risk, such as in those with recent fractures. Initial treatment selection should also consider the probability that a BMD treatment target can be attained within a reasonable period of time and the differential magnitude of fracture risk reduction and BMD impact with osteoanabolic versus antiresorptive therapy. This position statement of the ASBMR/BHOF Task Force on Goal-Directed Osteoporosis Treatment provides an overall summary of the major clinical recommendations about treatment targets and strategies to achieve those targets based on the best evidence available, derived primarily from studies in older postmenopausal women of European ancestry.
- Open Access
- 23 July 2024
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (9) , 1268-1277
Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension
Osteoanabolic-first treatment sequences are superior to oral bisphosphonates for fracture reduction and BMD gain. However, data comparing osteoanabolic medications with the more potent antiresorptive, denosumab (DMAb), are limited. We analyzed FRAME and FRAME Extension data to assess BMD and fracture incidence in patients treated with romosozumab (Romo) followed by DMAb (Romo/DMAb) versus DMAb (DMAb/DMAb) for 24 months. In FRAME, women aged ≥55 years (total hip [TH] or femoral neck [FN] T-score: –2.5 to. –3.5) were randomized to Romo or placebo for 12 months followed by DMAb for 12 months. In FRAME Extension, both cohorts received DMAb for another 12 months. This post-hoc analysis compared BMD change and fracture incidence in patients on Romo/DMAb (months 0-24) versus DMAb/DMAb (months 12-36). Patient characteristics were balanced by propensity score weighting (PSW) and sensitivity analyses were conducted using PSW with multiple imputation (PSW-MI) and propensity score matching (PSM). Unmeasured confounding was addressed using E-values. After PSW, over 24 months, compared with DMAb/DMAb, treatment with Romo/DMAb produced significantly greater BMD increases at the lumbar spine [LS], TH, and FN (mean differences: 9.3%, 4.4%, and 4.1%, respectively; all p < 0.001). At month 24, in women with a baseline T-score of –3.0, the probability of achieving a T-score > –2.5 was higher with Romo/DMAb versus DMAb/DMAb (LS:92% versus 47%; TH:50% versus 5%). In the Romo/DMAb versus DMAb/DMAb cohorts, new vertebral fractures were significantly reduced (0.62% versus 1.26% [odds ratio = 0.45; p = 0.003]) and rates of clinical, nonvertebral, and hip fractures were lower (differences not significant). Similar BMD and fracture outcomes were observed with PSW-MI and PSM sensitivity analyses. The sequence of Romo/DMAb resulted in greater BMD gains and higher probability of achieving T-scores > –2.5, significantly reduced new vertebral fracture incidence, and numerically lowered the incidence (not significant) of clinical, nonvertebral, and hip fractures versus DMAb only through 24 months. In patients with very high fracture risk, a treatment sequence with a bone-forming agent, followed by a bisphosphonate (one type of antiresorptive that reduces bone loss) is more effective in increasing bone mineral density (BMD) and reducing fracture risk compared to treatment with bisphosphonates alone. Here, we utilized patient data from the FRAME and FRAME Extension clinical trials to compare changes in BMD and fracture incidence in postmenopausal women with osteoporosis treated with the bone-forming agent, romosozumab (Romo), for 12 months followed by the most potent antiresorptive, denosumab (DMAb), for 12 months (Romo/DMAb) versus patients treated with DMAb alone for 24 months. Propensity score weighting was used to balance the patient characteristics between the two groups. We found that BMD gains were significantly higher in patients treated with the Romo/DMAb sequence versus DMAb alone; these patients also had a higher probability of achieving a T-score above the osteoporosis range (>–2.5). In addition, new vertebral fractures were significantly lower and rates of clinical, nonvertebral, and hip fractures trended lower in patients treated with the Romo/DMAb sequence versus DMAb alone. Thus, a 24-months treatment sequence of Romo/DMAb compared with DMAb alone, resulted in higher BMD gains and lower fracture risk.
- 23 July 2024
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (9) , 1268-1277
Open AccessRomosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension
Osteoanabolic-first treatment sequences are superior to oral bisphosphonates for fracture reduction and BMD gain. However, data comparing osteoanabolic medications with the more potent antiresorptive, denosumab (DMAb), are limited. We analyzed FRAME and FRAME Extension data to assess BMD and fracture incidence in patients treated with romosozumab (Romo) followed by DMAb (Romo/DMAb) versus DMAb (DMAb/DMAb) for 24 months. In FRAME, women aged ≥55 years (total hip [TH] or femoral neck [FN] T-score: –2.5 to. –3.5) were randomized to Romo or placebo for 12 months followed by DMAb for 12 months. In FRAME Extension, both cohorts received DMAb for another 12 months. This post-hoc analysis compared BMD change and fracture incidence in patients on Romo/DMAb (months 0-24) versus DMAb/DMAb (months 12-36). Patient characteristics were balanced by propensity score weighting (PSW) and sensitivity analyses were conducted using PSW with multiple imputation (PSW-MI) and propensity score matching (PSM). Unmeasured confounding was addressed using E-values. After PSW, over 24 months, compared with DMAb/DMAb, treatment with Romo/DMAb produced significantly greater BMD increases at the lumbar spine [LS], TH, and FN (mean differences: 9.3%, 4.4%, and 4.1%, respectively; all p < 0.001). At month 24, in women with a baseline T-score of –3.0, the probability of achieving a T-score > –2.5 was higher with Romo/DMAb versus DMAb/DMAb (LS:92% versus 47%; TH:50% versus 5%). In the Romo/DMAb versus DMAb/DMAb cohorts, new vertebral fractures were significantly reduced (0.62% versus 1.26% [odds ratio = 0.45; p = 0.003]) and rates of clinical, nonvertebral, and hip fractures were lower (differences not significant). Similar BMD and fracture outcomes were observed with PSW-MI and PSM sensitivity analyses. The sequence of Romo/DMAb resulted in greater BMD gains and higher probability of achieving T-scores > –2.5, significantly reduced new vertebral fracture incidence, and numerically lowered the incidence (not significant) of clinical, nonvertebral, and hip fractures versus DMAb only through 24 months. In patients with very high fracture risk, a treatment sequence with a bone-forming agent, followed by a bisphosphonate (one type of antiresorptive that reduces bone loss) is more effective in increasing bone mineral density (BMD) and reducing fracture risk compared to treatment with bisphosphonates alone. Here, we utilized patient data from the FRAME and FRAME Extension clinical trials to compare changes in BMD and fracture incidence in postmenopausal women with osteoporosis treated with the bone-forming agent, romosozumab (Romo), for 12 months followed by the most potent antiresorptive, denosumab (DMAb), for 12 months (Romo/DMAb) versus patients treated with DMAb alone for 24 months. Propensity score weighting was used to balance the patient characteristics between the two groups. We found that BMD gains were significantly higher in patients treated with the Romo/DMAb sequence versus DMAb alone; these patients also had a higher probability of achieving a T-score above the osteoporosis range (>–2.5). In addition, new vertebral fractures were significantly lower and rates of clinical, nonvertebral, and hip fractures trended lower in patients treated with the Romo/DMAb sequence versus DMAb alone. Thus, a 24-months treatment sequence of Romo/DMAb compared with DMAb alone, resulted in higher BMD gains and lower fracture risk.
- 22 July 2024
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (9) , 1371-1372
Letter to the editor regarding “The American Society for Bone and Mineral Research Task Force on clinical algorithms for fracture risk report”
To the editor: In a recent issue of the Journal of Bone and Mineral Research, The American Society for Bone and Mineral Research Task Force Report recommends that race/ethnicity be removed as a variable in FRAX. 1 As an interim measure, the Task Force recommends that non-White women be presented with a risk range. The lower boundary of the range would be the current FRAX race-specific estimate, and the upper boundary would be the risk derived from assigning White race to non-White women. The Task Force justifies this recommendation by pointing out that non-White women who sustain fractures have less favorable outcomes than White women. Herein, we consider the potential impact that implementing the Task Force interim recommendations would have on clinical practice in two sample cases: We commend the Task Force for addressing this important issue and for its research recommendations. We recognize the complexity of this question including the well-documented differences in BMD, fracture risk, and postfracture outcomes among racial groups in the United States. However, we have objections to the recommendation that race be removed from considering fracture risk in FRAX. Treating more low-risk patients is not the solution to the myriad factors resulting in poorer health outcomes among non-White persons.
- 22 July 2024
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (9) , 1371-1372
Letter to the editor regarding “The American Society for Bone and Mineral Research Task Force on clinical algorithms for fracture risk report”
To the editor: In a recent issue of the Journal of Bone and Mineral Research, The American Society for Bone and Mineral Research Task Force Report recommends that race/ethnicity be removed as a variable in FRAX. 1 As an interim measure, the Task Force recommends that non-White women be presented with a risk range. The lower boundary of the range would be the current FRAX race-specific estimate, and the upper boundary would be the risk derived from assigning White race to non-White women. The Task Force justifies this recommendation by pointing out that non-White women who sustain fractures have less favorable outcomes than White women. Herein, we consider the potential impact that implementing the Task Force interim recommendations would have on clinical practice in two sample cases: We commend the Task Force for addressing this important issue and for its research recommendations. We recognize the complexity of this question including the well-documented differences in BMD, fracture risk, and postfracture outcomes among racial groups in the United States. However, we have objections to the recommendation that race be removed from considering fracture risk in FRAX. Treating more low-risk patients is not the solution to the myriad factors resulting in poorer health outcomes among non-White persons.